To tackle these issues, a number of ALS-causative proteins including C9orf72, TDP-43 and FUS have been identified and studied for the development of ALS therapeutic agents selectively targeting these molecules (6, 7). This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.